Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

Healthcare

Page 84
  1. Dec 17, 2025 · 17:01 · VIVI

    TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida

    TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida

    01
  2. Dec 17, 2025 · 10:59 · BNXT

    Bionxt Solutions talks up sublingual thin-film product

    Bionxt Solutions talks up sublingual thin-film product

    02
  3. Dec 17, 2025 · 08:02 · BIOV

    BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

    BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

    03
  4. Dec 17, 2025 · 08:00 · UDOC

    UniDoc Completes H3 Health Cube Installation in Italy

    UniDoc Completes H3 Health Cube Installation in Italy

    04
  5. Dec 17, 2025 · 07:30 · LSL

    LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M

    LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M

    05
  6. Dec 17, 2025 · 07:25 · KNE

    Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting

    Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting

    06
  7. Dec 17, 2025 · 03:05 · BNXT

    Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film "Melt-in-Your-Mouth" Therapies

    Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film "Melt-in-Your-Mouth" Therapies

    07
  8. Dec 16, 2025 · 19:00 · NLH

    Nova Leap rolls out care management division in U.S.

    Nova Leap rolls out care management division in U.S.

    08
  9. Dec 16, 2025 · 18:32 · AIAI

    Netramark, CAMH win Ontario research award

    Netramark, CAMH win Ontario research award

    09
  10. Dec 16, 2025 · 08:30 · AIAI

    NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression

    NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression

    10
  11. Dec 16, 2025 · 08:16 · NLH

    Nova Leap Health Corp. Launches Care Management Division In the United States

    Nova Leap Health Corp. Launches Care Management Division In the United States

    11
  12. Dec 16, 2025 · 07:40 · ARCH

    Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

    Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

    12
  13. Dec 15, 2025 · 18:25 · AIAI

    Netramark completes FDA AI meeting

    Netramark completes FDA AI meeting

    13
  14. Dec 15, 2025 · 17:52 · QIPT

    Quipt signs deal for acquisition by Kingswood, Forager

    Quipt signs deal for acquisition by Kingswood, Forager

    14
← Newer Older →